Northwest Biotherapeutics, Inc.
NWBO
$0.17
$0.000.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 98.63% | 1.63% | -0.29% | -41.29% | -33.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 98.63% | 1.63% | -0.29% | -41.29% | -33.50% |
| Cost of Revenue | -31.56% | -28.35% | -17.49% | 6.08% | 11.47% |
| Gross Profit | 35.83% | 29.65% | 18.20% | -8.58% | -14.00% |
| SG&A Expenses | -9.72% | -13.26% | -1.50% | -2.54% | -2.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.03% | -20.92% | -9.72% | 1.70% | 4.17% |
| Operating Income | 23.03% | 21.41% | 9.91% | -2.78% | -5.17% |
| Income Before Tax | 53.51% | 47.62% | 27.55% | -29.11% | -11.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.16% | 48.25% | 28.19% | -29.11% | -11.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.16% | 48.25% | 28.19% | -29.11% | -11.72% |
| EBIT | 23.03% | 21.41% | 9.91% | -2.78% | -5.17% |
| EBITDA | 25.18% | 22.95% | 10.68% | -2.79% | -5.21% |
| EPS Basic | 59.71% | 54.19% | 37.19% | -11.21% | 2.79% |
| Normalized Basic EPS | 32.93% | 38.06% | 28.01% | 0.29% | 7.61% |
| EPS Diluted | 57.50% | 52.45% | 36.54% | -6.15% | -4.18% |
| Normalized Diluted EPS | 32.93% | 38.06% | 28.01% | 0.29% | 7.61% |
| Average Basic Shares Outstanding | 16.61% | 17.72% | 17.24% | 16.14% | 14.24% |
| Average Diluted Shares Outstanding | 16.61% | 17.72% | 17.24% | 16.14% | 14.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |